| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Depts of Immunology and Medicine, Landspitali - University Hospital, Reykjavik, Iceland, 2 Dept of Immunology, University Medical Centre Utrecht (UMCU), Utrecht, The Netherlands, 3 Dept of Microbiology and Immunology, State University of New York Science Center at Brooklyn, Brooklyn, NY, USA, 4 Laboratory of Developmental and Molecular Immunology, National Institute of Child Health and Human Development, Bethesda, MD, USA
CORRESPONDENCE: I. Jonsdottir, Dept of Immunology, Landspitali - University Hospital, Hringbraut, 101 Reykjavik, Iceland. Fax: 354 5601943. E-mail: ingileif@landspitali.is
Keywords: antibodies, chronic obstructive pulmonary disease, opsonophagocytosis, pneumococcus, vaccination
Received: October 25, 2001
Accepted April 12, 2002
The study was funded by the Science Fund of the Icelandic Research Council and The Icelandic Ministry of Health and Social Security.
This paper examines how pneumococcal type 6B polysaccharide conjugated to tetanus toxoid (Pn6B-TT) compares to a 23 valent pneumococcal vaccine (pneumococcal polysaccharide (PPS)-23) with respect to immunogenicity and serum opsonic activity in patients with chronic obstructive pulmonary disease (COPD).
Patients with COPD aged 55–75 yrs were vaccinated with Pn6B-TT (n=10) or with PPS-23 (n=9). Healthy young adults (HA) were vaccinated with Pn6B-TT as controls. Total antibodies to serotype 6B polysaccharide were measured by radioimmunoassay and immunoglobulin (Ig)G antibodies by enzyme-linked immunosorbent assay. Opsonic activity was measured by a phagocytosis assay using human neutrophils as effector cells.
The patient groups were comparable by age, smoking history, lung function and use of steroids. COPD patients vaccinated with Pn6B-TT or PPS-23 showed an increase in IgG antibodies and a nonsignificant increase in opsonic activity. This was similar to the increase in IgG and opsonic activity seen in HA. There was a significant correlation between antibody levels and opsonic activity in COPD patients vaccinated both with Pn6B-TT and PPS-23.
Pneumococcal antibodies have been shown to confer protection from infection. The results of the present study indicate that protective immunity can be expected in elderly chronic obstructive pulmonary disease patients vaccinated with conjugate vaccines.
This article has been cited by other articles:
|
|
 |
|
  J. G. Schenkein, M. H. Nahm, and M. T. Dransfield Pneumococcal Vaccination for Patients With COPD: Current Practice and Future Directions Chest, March 1, 2008; 133(3): 767 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Woodhead, F. Blasi, S. Ewig, G. Huchon, M. Leven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, and T. J. M. Verheij Guidelines for the management of adult lower respiratory tract infections Eur. Respir. J., December 1, 2005; 26(6): 1138 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bogaert, P. van der Valk, R. Ramdin, M. Sluijter, E. Monninkhof, R. Hendrix, R. de Groot, and P. W. M. Hermans Host-Pathogen Interaction during Pneumococcal Infection in Patients with Chronic Obstructive Pulmonary Disease Infect. Immun., February 1, 2004; 72(2): 818 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Wernette, C. E. Frasch, D. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S. A. Quataert, S. Hildreth, D. J. Sikkema, et al. Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal Polysaccharides Clin. Vaccine Immunol., July 1, 2003; 10(4): 514 - 519. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
